Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Inc. (INSM) Chair and CEO William Lewis reported a series of option exercises and related stock sales on January 12, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. He exercised stock options for 6,259 shares of common stock at $30.46 per share and 4,440 shares at $17.16 per share, converting these into common shares.
On the same date he sold multiple blocks of Insmed common stock, including 3,974 shares at a weighted average price of $167.73 and 7,176 shares at $168.63, with additional smaller sales up to $174.86 per share. After these transactions, he directly owned 306,891 shares of common stock and indirectly held 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust. He also held 81,368 and 57,720 stock options remaining from the exercised grants.
Insmed Inc.'s Chief Medical Officer, Martina Flammer, reported a sale of company common stock. On January 9, 2026, she sold 1,887 shares of Insmed common stock at a price of $186.19 per share, as shown in Table I of the filing.
The filing states that this transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After this sale, Flammer beneficially owns 84,907 shares of Insmed common stock, held directly.
Insmed shareholder William Lewis has filed a notice of proposed stock sales under Rule 144. The filing covers the planned sale of 19,215 shares of Insmed common stock through Merrill Lynch on the NASDAQ around 01/12/2026, with an aggregate market value of 3,247,325. The company reports 213,273,469 shares of common stock outstanding. The shares to be sold were acquired through stock plan activity from the issuer on several dates in January 2026, including 10,699 shares on 01/12/2026. Over the prior three months, William Lewis sold additional Insmed common shares, including 10,699 shares on both 12/04/2025 and 12/18/2025, and smaller blocks in January 2026, with disclosed gross proceeds for each transaction.
Insmed Incorporated reported that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). The company will provide a live webcast of the presentation through the investor relations section of its website, allowing broader access for interested stakeholders. In connection with this conference appearance, Insmed issued a press release and prepared a slide presentation, which are included as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference for informational purposes but are not deemed filed under securities laws.
Sara Bonstein filed a notice of proposed sale of common stock of the issuer under Rule 144. The planned sale covers 1,447 common shares through Merrill Lynch on 01/08/2026 on NASDAQ, with an aggregate market value of 252,023 and 213,273,469 shares outstanding.
The 1,447 shares were acquired on 01/06/2026 via stock plan activity from the issuer, with payment also dated 01/06/2026. Over the past three months, the seller reported additional sales of common stock, including 1,678 shares on 01/07/2026 for gross proceeds of 293,766 and 1,517 shares on 01/06/2026 for gross proceeds of 262,941.
Insmed submitted a notice of proposed sale under Rule 144 for 5,138 common shares, to be sold through Merrill Lynch on the NASDAQ around 01/08/2026. The filing lists an aggregate market value of 894,885 for these shares and notes that common shares outstanding total 213,273,469.
The securities to be sold were acquired from the issuer through stock plan activity on 01/04/2026, 01/05/2026, and 01/06/2026 in amounts of 1,603, 1,648, and 1,887 common shares, respectively. The person for whose account the shares are to be sold, identified as Martina Flammer, previously sold common shares over the past three months, including 31,226 shares on 11/11/2025 for gross proceeds of 5,921,820 and 12,303 shares on 01/05/2026 for gross proceeds of 2,108,459.
A shareholder associated with symbol INSM has filed a Form 144 indicating an intention to sell 1,660 shares of common stock through Merrill Lynch on or about 01/08/2026 on the NASDAQ market. The filing notes that 213,273,469 shares of this class of stock were outstanding at the time.
The 1,660 shares to be sold were acquired on 01/06/2026 through stock plan activity from the issuer. The filer, Martina Flammer, also reported several recent sales in the past three months, including 31,226 shares sold on 11/11/2025 for gross proceeds of 5,921,820 and other transactions such as 12,303 shares on 01/05/2026 for gross proceeds of 2,108,459. The signer represents that they are not aware of undisclosed material adverse information about the issuer.
Insmed Inc. insider Roger Adsett filed a notice of proposed sale of 2,059 shares of common stock, with an aggregate market value of 358,616, to be sold on or about 01/08/2026 through Merrill Lynch on the NASDAQ. These shares were acquired on 01/06/2026 via stock plan activity from the issuer. Over the past three months, Adsett has sold 802 common shares for gross proceeds of 140,406 on 01/07/2026 and 1,429 common shares for gross proceeds of 247,688 on 01/06/2026. Shares of the issuer outstanding are reported as 213,273,469.
Insmed Inc. Chief Operating Officer Roger Adsett reported three sales of Insmed common stock in early January. On January 6, 2026, he sold 1,429 shares at $173.33 per share. On January 7, 2026, he sold 802 shares at $175.07 per share, and on January 8, 2026, he sold 2,059 shares at $174.17 per share.
After these transactions, Adsett directly held 107,601 Insmed shares. A footnote explains that the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units and to cover related broker fees, indicating these were primarily tax-related transactions rather than discretionary sales.
Insmed Inc. reported that its Chief Financial Officer, Sara Bonstein, sold small blocks of common stock on three consecutive days to cover tax obligations tied to equity awards. On January 6, 2026, she sold 1,517 shares at $173.33 per share, on January 7, 2026 she sold 1,678 shares at $175.07 per share, and on January 8, 2026 she sold 1,447 shares at $174.17 per share. According to the filing, these sales were made to satisfy tax withholding obligations upon the vesting of restricted stock units and to cover related broker fees, and she directly owned 80,506 shares of common stock after the final transaction.